Keyan Salari, MD, PhD
Keyan Salari, MD, PhD
Urologic Oncologist | Urologic Surgeon
Assistant in Urology, Massachusetts General Hospital
Urologic Oncologist, MGH Cancer Center
Instructor in Surgery, Harvard Medical School
Assistant in Urology, Massachusetts General Hospital
Urologic Oncologist, MGH Cancer Center
Instructor in Surgery, Harvard Medical School
About Keyan Salari, MD, PhD
Departments, Centers, & Programs:
Clinical Interests:
- Prostate cancer
- Testicular cancer
- Renal Cancer
- Bladder cancer
- Ureteral Cancer
- Penile cancer
- Urethral Cancer
- Laparoscopic surgery, Robotic surgery, Open surgery
- Minimally invasive surgery
Treats:
- Adult
Languages:
- Persian/Farsi
Locations
Urology Associates
165 Cambridge St
7th Floor
Boston, MA 02114-2783
857-238-3838
Fax: 617-726-6131
MGH Cancer Center
Center for Genitourinary Cancers
55 Fruit Street, Yawkey 7E
Boston, MA 02114
617-726-5130
Medical Education
- PhD, Stanford University
- MD, Stanford University School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Memorial Sloan Kettering Cancer Center
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
View my most recent publications at PubMed
- Hanna N, Wszolek MF, Mojtahed A, Nicaise E, Wu B, Gelpi-Hammerschmidt FJ, Salari K, Dahl DM, Blute ML, Harisinghani M, Feldman AS. Multiparametric MRI/ultrasound fusion biopsy improves but does not replace standard template biopsy for the detection of prostate cancer. J Urol. 2019 May 30.
- Salari K, Kuppermann D, Preston MA, Dahl DM, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years. J Urol. 2019 Apr;201(4):721-727.
- Wang Z, Hu L, Salari K, Bechis SK, Ge R, Wu S, Rassoulian C, Pham J, Wu CL, Tabatabaei S, Strand D, Olumi AF. Androgenic to Estrogenic Switch in Human Adult Prostate Gland as a result of Epigenetic Silencing of Steroid 5-α Reductase 2. J Pathol. 2017 Dec;243(4):457-467.
- Cuff J, Salari K, Esheba GE, Huang S, West RB, Higgins JP, Longacre TA, Pollack JR. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS ONE 2013 Sep 9;8(9):e74562.
- Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, Ko ME, Lin AY, van de Rijn M, Pollack JR. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci USA. 2012 Nov 13;109(46):E3196-205.
- Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene. 2012 Sep 13;31(37):4164-70.
- Salari K, Tibshirani R, Pollack JR. DR-Integrator: a new analytic tool for integrating DNA copy number and gene expression data. Bioinformatics. 2010 Feb 1;26(3):414-6.